Table 2.
Concomitanta treatments (%), overall and stratified by duration of ITP at romiplostim initiation
| Overall (n = 340) |
ITP duration (months) | |||
|---|---|---|---|---|
| < 3 (n = 64) |
3–12 (n = 50) |
> 12 (n = 226) |
||
| Oral steroid | 120 (35.3%) | 25 (39.1%) | 18 (36.0%) | 77 (34.1%) |
| IV anti-D | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| IVIg | 25 (7.4%) | 6 (9.4%) | 4 (8.0%) | 15 (6.6%) |
| IV steroid | 11 (3.2%) | 4 (6.2%) | 2 (4.0%) | 5 (2.2%) |
| Azathioprine | 5 (1.5%) | 1 (1.6%) | 1 (2.0%) | 3 (1.3%) |
| Alemtuzumab | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Cyclophosphamide | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Cyclosporine | 6 (1.8%) | 0 (0%) | 2 (4.0%) | 4 (1.8%) |
| Danazol | 4 (1.2%) | 0 (0%) | 0 (0%) | 4 (1.8%) |
| Dapsone | 4 (1.2%) | 0 (0%) | 0 (0%) | 4 (1.8%) |
| Mycophenolate | 2 (0.6%) | 0 (0%) | 0 (0%) | 2 (0.9%) |
| Rituximab | 7 (2.1%) | 2 (3.1%) | 1 (2.0%) | 4 (1.8%) |
| Vinca alkaloids | 2 (0.6%) | 1 (1.6%) | 0 (0%) | 1 (0.4%) |
| Platelet transfusion | 12 (3.5%) | 6 (9.4%) | 2 (4.0%) | 4 (1.8%) |
| Number of ITP treatments received, median (Min, Max) | 0.0 (0.0, 5.0) | 1.0 (0.0, 3.0) | 0.0 (0.0, 3.0) | 0.0 (0.0, 5.0) |
| Number of concomitant ITP treatments received category | ||||
| 0 | 180 (52.9%) | 28 (43.8%) | 26 (52.0%) | 126 (55.8%) |
| 1 | 127 (37.4%) | 28 (43.8%) | 19 (38.0%) | 80 (35.4%) |
| 2 | 30 (8.8%) | 7 (10.9%) | 4 (8.0%) | 19 (8.4%) |
| 3 + | 3 (0.9%) | 1 (1.6%) | 1 (2.0%) | 1 (0.4%) |
ITP immune thrombocytopenia, IV intravenous
aMedications were considered concomitant if the index romiplostim date fell between or on the start or end date of the medication